Get the Stockscreener App
0.485
2.22%
-0.011
Gri Bio Inc stock is traded at $0.485, with a volume of 96,685.
It is down -2.22% in the last 24 hours and down -41.33% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$0.496
Open:
$0.497
24h Volume:
96,685
Relative Volume:
0.11
Market Cap:
$4.43M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.00905
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
-23.26%
1M Performance:
-41.33%
6M Performance:
+5.43%
1Y Performance:
-96.89%
1-Day Range:
$0.4658
$0.523
1-Week Range:
$0.4658
$0.66
52-Week Range:
$0.3015
$21.06
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
0.4851 | 4.43M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.44 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
717.60 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.43 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.82 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.90 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
Analyzing the Price-to-Earnings Ratio of GRI Bio Inc (GRI) - The News Heater
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Phibro Animal Health (NASDAQ:PAHC) and GRI Bio (NASDAQ:GRI) Critical Review - Defense World
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust - GlobeNewswire
IN8bio Inc (NASDAQ: INAB): What’s Next After The Stock Plunge? - Stocks Register
Windtree Therapeutics Appoints Leanne Kelly to Board of Directors and Audit Committee - Defense World
Windtree Therapeutics Appoints Leanne Kelly to Board, Advances New Growth Strategy - MyChesCo
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors - The Manila Times
Windtree Therapeutics Strengthens Board with Biotech Finance Veteran Leanne Kelly - StockTitan
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
Pre-market Movers: HSDT, PBM, MTEM, APTO... - RTTNews
The GRI Marketing Group Joins SDL to Accelerate North America CX Growth Strategy - Yahoo Finance
Short Interest in GRI Bio, Inc. (NASDAQ:GRI) Increases By 155.5% - Defense World
FLYHT Aerospace Solutions Ltd. (OTCMKTS:FLYLF) Sees Significant Growth in Short Interest - Defense World
Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and - EIN News
GRI Bio Announces European Patent Office Issued a Decision - GlobeNewswire
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds - GlobeNewswire Inc.
Mainz Biomed stock higher on Quest deal (MYNZ:NASDAQ) - Seeking Alpha
GRI Bio (NASDAQ:GRI) Now Covered by HC Wainwright - Defense World
GRI Bio Inc (NASDAQ: GRI): What’s Next After The Stock Plunge? - Stocks Register
Astera Labs Inc: Is ALAB Stock Worth Buying? - Stocks Register
Pre-market Movers: SXTC, STIM, BIOA, UPC... - RTTNews
GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
GRI Bio to Present Corporate Strategy at Virtual Investor Closing Bell Series - StockTitan
GRI Bio reports progress in IPF treatment with GRI-0621 - Investing.com India
GRI Bio Showcases GRI-0621’s Potential to Reduce - GlobeNewswire
GRI Bio's IPF Drug Shows Promise in Preclinical Data, Phase 2a Trial Underway | GRI Stock News - StockTitan
GRI Bio files to sell 1.58M shares of common stock for holders - MSN
SEC Form 424B3 filed by GRI Bio Inc. - Quantisnow
GRI Bio Inc (GRI) Quarterly 10-Q Report - Quartzy
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis - GlobeNewswire
GRI Bio Raises $13.9M, Extends Runway for Key IPF Drug Trial Data in 2025 | GRI Stock News - StockTitan
GRI Bio Inc expected to post a loss of 73 cents a shareEarnings Preview - XM
Ascendiant Capital Initiates Coverage of GRI Bio (GRI) with Buy Recommendation - MSN
Beam Therapeutics (BEAM) Stock Surges with Strong Trading Volume - GuruFocus.com
Curis (CRIS) Stock Plummets Over 5% Amid Lack of Institutional R - GuruFocus.com
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
Primary Sclerosing Cholangitis Pipeline 2024: Clinical Trials - openPR
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.80% - MSN
GRI Bio secures funding to advance IPF treatment into 2025 - Investing.com India
GRI Bio secures funding to advance IPF treatment into 2025 By Investing.com - Investing.com UK
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024 - GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Dow Falls Over 150 Points; General Motors Tops Q3 Views - Benzinga
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.80% - MSN
GRI Bio Announces Exercise of Warrants - GlobeNewswire
Dyne Therapeutics (DYN) Shares Plummet Amid Market Volatility - GuruFocus.com
Top Innovation Stocks Surge: PRSO, SYTA, SAVE, ISPC, GRI, BIVIMust-Watch Stocks This Week - openPR
Energy storage ‘key’ to sustainability – report - Yahoo! Voices
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):